Patients With RETT Syndrome

Learn more about:
Related Clinical Trial
The Role of Dietary Calcium for the Treatment of Osteopenia in Girls With Rett Syndrome Measuring Impact of Computer Gaming on Arm Use in Rett Syndrome An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome Development of the ORCA Communication Measure for Rett Syndrome The Rett Syndrome Global Registry Open-Label Extension Study of Trofinetide for Rett Syndrome ASSESSING EMERALD AND MC10 BIOSTAMP nPOINT BIOSENSORS FOR RETT SYNDROME Predictors of Caregiver Adaptation to Pervasive Developmental Disorders A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Children With Autistic Disorder and Other Pervasive Developmental Disorders (PDD) New Genes Involved in Molecular Etiology of Rett Syndrome Through DNA Microarray Comparative Genomic Hybridization An Open-label Extension Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome ANAVEX2-73 Study in Patients With Rett Syndrome Study of Cardiac and Paroxysmal Abnormalities in Rett Syndrome Nutritional Aspects of Rett Syndrome Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW Study of the Pathogenesis of Rett Syndrome Advanced Grandparental Age as a Risk Factor for Autism A Safety Study of NNZ-2566 in Pediatric Rett Syndrome Treatment of Mitochondrial Dysfunction in Rett Syndrome With Triheptanoin Biobanking of Rett Syndrome and Related Disorders Telehealth Support to Increase Physical Activity in Rett Syndrome Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome An Open Label, Exploratory Study to Investigate the Treatment Effect of Glatiramer Acetate on Girls Woth Rett Syndrome Natural History of Rett Syndrome & Related Disorders Independent Studies of Dextromethorphan and of Donepezil Hydrochloride for Rett Syndrome Study of ANAVEX2-73 in Patients With Rett Syndrome Trial of Dextromethorphan in Rett Syndrome Pharmacological Treatment of Rett Syndrome With Statins An Exploratory Trial of Ketamine for the Treatment of Rett Syndrome Analysis of the Glutathione Cycle in Children With Rett Syndrome Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome ‘Uptime’ Participation Intervention in Girls and Women With Rett Syndrome Functional Abilities in Rett Syndrome Treatment of Rett Syndrome With rhIGF-1 (Mecasermin [rDNA]Injection) Placebo Controlled Trial of Dextromethorphan in Rett Syndrome Effects of Creatine Supplementation in Rett Syndrome Metabolic Evaluation of Nutrition in Rett Syndrome Treatment of Rett Syndrome With Recombinant Human IGF-1 A Study to Evaluate Ketamine for the Treatment of Rett Syndrome Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms A Safety Study of NNZ-2566 in Patients With Rett Syndrome Genetic and Physical Characteristics of Rett Syndrome Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™) The Role of Family Functioning in Adaptation to Being a Caregiver of an Individual With Rett Syndrome A Pilot Study of an Antioxidant Cocktail vs. Placebo in the Treatment of Children and Adolescents With Rett Syndrome The Findings of MR Imaging in Rett Syndrome Phase 2 Study of EPI-743 for Treatment of Rett Syndrome Open Label Trial of Triheptanoin (UX007) in Treatment of Rett Syndrome. Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone) Study to Assess Safety and Efficacy of Fingolimod in Children With Rett Syndrome Pilot Study of the Effects of the Desipramine on the Neurovegetative Parameters of the Child With Rett Syndrome Patients With RETT Syndrome Creatine Metabolism in Rett Syndrome

Brief Title

Patients With RETT Syndrome

Official Title

Study of Biological Parameters in 100 Girls With RETT Syndrome

Brief Summary

      It was proposed to the French Association of Rett Syndrome (AFSR) to perform an extensive
      biological assessment in a series of 100 girls with Rett's syndrome and carriers of a
      mutation in the MECP2 gene in order to confirm or confirm to reverse the abnormalities
      identified previously and possibly, to highlight new biomarkers of the pathology. The
      analysis will focus on classical hematological criteria, iron markers, endocrine assays,
      lipid quantification and markers of inflammation. At the end of the project, each family will
      receive the complete biological assessment carried out on their daughter which will represent
      a direct benefit of the implication in this clinical research project.
    

Detailed Description

      The MECP2 (Methyl-CpG binding protein) gene, located on the X X28 chromosome, encodes a
      heterochromatin nuclear protein. Mecp2 is preferentially found in neurons at a postmitotic
      stage where it promotes brain development. Its ability to fix methylated DNA and contribute
      to the formation of a transcriptional repression complex attributes this protein to a crucial
      role in the control of gene expression. However, until today, its exact role is not known. In
      humans, mutations in the MECP2 gene are at the origin of neurological diseases, the main one
      being Rett's syndrome (RTT-MIM # 312750) where a mutation of MECP2 is found in 95% of cases.
      This dominant pathology linked to the X chromosome has a prevalence of 1/10000 to 1/15000
      births and affects mostly girls. The course of the pathology is characterized by a cessation
      of development between 6 and 18 months after birth. Patients present a set of characteristic
      signs including regression of acquired abilities, manual stereotyping, loss of language,
      behavioral disorders and severe intellectual disability. In their attempt to better
      understand the pathology, many laboratories are currently trying to identify abnormal
      biological parameters in patients that are easy to identify in a non-invasive or minimally
      invasive way in order to indirectly evaluate the progression of the pathology and to identify
      biochemical disorders amenable to direct pharmacological intervention.

      In autumn 2015, several factors were identified as deregulated in model mice or RTT patients
      (Rett syndrome). They could be related to the severity of the disease and indicators of its
      progression. Among these we can mention:

        -  major structural damage to red blood cells;

        -  Inflammation demonstrated and challenged ;

        -  high oxidative stress markers; lipid deregulation and in particular cholesterol
           abnormalities;

        -  a deficiency of the signaling pathway of insulin and IGF-1.
    


Study Type

Interventional


Primary Outcome

Comparison of red blood cell morphology


Condition

Rett Syndrome

Intervention

An extensive biological assessment

Study Arms / Comparison Groups

 Girls with RETT syndrome
Description:  100 girls over 18 years old with RETT syndrome

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Other

Estimated Enrollment

100

Start Date

September 1, 2019

Completion Date

October 1, 2020

Primary Completion Date

October 1, 2019

Eligibility Criteria

        Inclusion Criteria:

          -  People with Rett syndrome related to MECP2 gene mutation

          -  Aged under 18 years old.

          -  Regularly followed as part of their illness by Prof. Bahi-Buisson in Necker or Pr Milh
             in Marseille.

          -  Whose state of health justifies a blood test (dosage of one or more anti-epileptics,
             recommended annual phosphocalcic balance, pre-therapeutic assessment before
             introduction of a new molecule ...)

          -  Whose at least one parent (or legal representative) has signed the consent

          -  Patient fasting for 6 hours at the time of sampling.

        Exclusion Criteria:

          -  Contraindication to a balance sheet

          -  Absence of consent of the legal representatives
      

Gender

Female

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Jean-Olivier ARNAUD, , [email protected]

Location Countries

France

Location Countries

France

Administrative Informations


NCT ID

NCT04014985

Organization ID

2018-30

Secondary IDs

2018-A01066-49

Responsible Party

Sponsor

Study Sponsor

Assistance Publique Hopitaux De Marseille


Study Sponsor

Jean-Olivier ARNAUD, Study Director, Assistance Publique Hôpitaux de Marseille


Verification Date

July 2019